



August 7, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 Terumo Corporation [IFRS]

Company name: TERUMO CORPORATION
 Listing: Tokyo Stock Exchange
 Securities code: 4543
 URL: <https://www.terumo.com/>
 Representative: Hikaru Samejima, Chief Executive Officer
 Inquiries: Jin Hagimoto, Chief Financial Officer, Chief Information Officer
 Telephone: +81-3-6742-8550
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for Securities analysts, Institutional investors)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative) (Percentages indicate year on year changes.)

	Revenue		Operating profit		Profit before tax		Profit for the period		Profit attributable to owners of the parent		Total comprehensive income	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	311,810	19.9	89,480	60.1	90,321	63.5	70,426	68.3	70,426	68.3	99,579	406.6
June 30, 2025	259,965	0.7	55,885	25.2	55,259	21.1	41,843	23.5	41,843	23.5	19,654	(81.7)

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	47.74	47.73
June 30, 2025	28.37	28.36

(Note) Adjusted operating profit June 2026: 79,607 million yen June 2025: 59,103 million yen

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
June 30, 2026	2,374,093	1,662,023	1,662,023	70.0
March 31, 2026	2,312,234	1,584,509	1,584,509	68.5

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	—	15.00	—	15.00	30.00
Fiscal year ending March 31, 2027	—				
Fiscal year ending March 31, 2027 (Guidance)		18.00	—	18.00	36.00

(Note) Revision from the dividend guidance published most recently: None

3. Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year on year changes.)

	Revenue		Adjusted operating profit		Operating profit		Profit for the year attributable to owners of the parent		Basic Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full fiscal year	1,239,000	9.5	274,500	25.1	257,500	46.0	193,100	42.1	130.91

(Note 1) Revision of guidance published most recently: Yes

Please refer to the “Notice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2027 (FY2026)” released on August 7, 2026.

(Note 2) Assumed exchange rate: 1USD=155 JPY, 1EUR=180 JPY

*Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: — (Company Name: —)

Excluded : — (Company Name: —)

(2) Changes in accounting policies and changes in accounting estimates

(i) Changes in accounting policies required by IFRS: Yes

(ii) Changes in accounting policies other than (i): None

(iii) Changes in accounting estimates: None

Note: Please refer to [attached materials], page 14, “2. Condensed Quarterly Consolidated Financial Statements (5) Notes to Condensed Quarterly Consolidated Financial Statements (ii) Changes in accounting policy”.

(3) Number of shares outstanding (common stock)

(i) Number of shares outstanding at the end of the period (including treasury shares)

As of June 30, 2026	1,480,559,680 shares	As of March 31, 2026	1,480,559,680 shares
As of June 30, 2026	5,458,187 shares	As of March 31, 2026	5,476,639 shares
Three months ended June 30, 2026	1,475,101,010 shares	Three months ended June 30, 2025	1,474,952,053 shares

(ii) Number of treasury shares at the end of the period

(iii) Average number of shares during the period (cumulative from the beginning of the fiscal year)

* Review of Japanese-language originals of the attached consolidated financial statements by certified public accountants or an audit firm: None

* Explanation on appropriate use of financial guidance and other special notes

1. Forward-looking statements, including financial guidance, contained in these disclosure materials, are based on information currently available to the Company and on certain assumptions deemed reasonable by management. These statements are not intended as a promise or commitment by the Company to achieve such results. Actual results may differ materially from these statements due to a variety of factors. For the assumptions underlying the financial guidance and notes on the use of such guidance, please refer to [attached materials], page 6, “1. Overview of Financial Results (4) Future Outlook concerning Consolidated Financial Guidance”.

2. Adjusted operating profit is defined as operating profit adjusted to exclude amortization of intangible assets acquired through business combinations and non-recurring profit or loss. Adjusted operating profit is consistent with segment profit and is disclosed as it is used as a performance indicator for the Group.

○ Table of contents of attached materials

1. Overview of Financial Results.....	2
(1) Overview of Consolidated Business Results.....	2
(2) Overview of Consolidated Statement of Financial Position.....	5
(3) Cash flow trends.....	5
(4) Future Outlook concerning Consolidated Financial Guidance.....	6
2. Condensed Quarterly Consolidated Financial Statements.....	7
(1) Condensed Quarterly Consolidated Statement of Financial Position.....	7
(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income	9
(3) Condensed Quarterly Consolidated Statement of Changes in Equity	11
(4) Condensed Quarterly Consolidated Statement of Cash Flows	12
(5) Notes to Condensed Quarterly Consolidated Financial Statements	14
(i) Going concern assumption.....	14
(ii) Change in accounting policy.....	14
(iii) Segment information	14
(iv) Material subsequent events.....	17

1. Overview of Financial Results

(1) Overview of Consolidated Business Results

In the three months of the current fiscal year (from April 1 to June 30, 2026), the Group's sales trended strongly amid growing demand globally and the effects of foreign exchange rates.

Financial results for the three months are as follows:

(Unit: Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026	Growth (%)	Growth excluding FX impact (%)
Revenue	259,965	311,810	19.9	9.4
Gross profit	145,467	178,538	22.7	13.3
Adjusted operating profit	59,103	79,607	34.7	25.3
Operating profit	55,885	89,480	60.1	48.7
Profit before tax	55,259	90,321	63.5	-
Profit for the period	41,843	70,426	68.3	-
Profit for the period attributable to owners of the parent	41,843	70,426	68.3	-

Revenue by geographic area for the three months is as follows:

(Unit: Millions of yen)

Geographic area	For the three months ended June 30, 2025	For the three months ended June 30, 2026	Growth (%)	Growth excluding FX impact (%)
Americas	100,503	126,140	25.5	12.2
Europe	54,299	67,389	24.1	11.9
China	22,935	27,955	21.9	3.4
Asia and others	29,419	35,558	20.9	10.0
Overseas total	207,158	257,044	24.1	10.8
Japan	52,807	54,765	3.7	3.7
Total	259,965	311,810	19.9	9.4

Revenue

Revenue totaled ¥311.8 billion, an increase of 19.9% compared to the same period of the previous fiscal year. Overseas, revenue increased by 24.1% year on year, due to expansion in the Terumo Interventional Systems division, centered on access devices, and growth in the key businesses of the Blood and Cell Technologies Company, along with the effects of foreign exchange rates.

In Japan, revenue increased by 3.7% year on year, due to strong sales in the Terumo Neuro division, the Hospital Care Solutions division, and the Pharmaceutical Solutions division.

Profit

Gross profit totaled ¥178.5 billion, an increase of 22.7% compared to the same period of the previous fiscal year, primarily due to higher revenue and the refund of U.S. tariffs.

Adjusted operating profit totaled ¥79.6 billion, an increase of 34.7% compared to the same period of the previous fiscal year, because of the higher gross profit.

Operating profit, profit for the period and profit for the period attributable to owners of the parent all increased due to the increase in gross profit and the recognition of settlement proceeds.

The Group discloses adjusted operating profit as a supplementary performance indicator that is not defined under IFRS, the accounting standards applied by the Group. Adjusted operating profit is defined as operating profit adjusted to exclude amortization of intangible assets acquired through business combinations and non-recurring profit or loss, and is consistent with segment profit.

The Group uses adjusted operating profit for management purposes to assess the performance of each business as it aims to achieve sustainable growth over the mid- to long-term. The Group also believes that this indicator provides useful information for users of the financial statements in evaluating the Group's performance.

Revenue results of the reportable segments are as follows:

(Unit: Millions of yen)

Segment		For the three months ended June 30, 2025	For the three months ended June 30, 2026	Growth (%)	Growth excluding FX impact (%)
Cardiac and Vascular Company	Revenue	157,827	188,141	19.2	7.3
	(Overseas)	143,773	174,215	21.2	8.1
	(Japan)	14,054	13,925	(0.9)	(0.9)
Medical Care Solutions Company	Revenue	50,402	56,587	12.3	8.5
	(Overseas)	14,393	18,705	30.0	16.1
	(Japan)	36,009	37,881	5.2	5.2
Blood and Cell Technologies Company	Revenue	51,646	60,776	17.7	6.1
	(Overseas)	48,991	57,897	18.2	6.0
	(Japan)	2,654	2,879	8.5	8.5
Terumo Organ Technologies	Revenue	-	6,225	-	-
	(Overseas)	-	6,225	-	-
	(Japan)	-	-	-	-

Cardiac and Vascular Company

Overseas, revenue increased by 21.2% year on year, due to growth across all businesses, particularly in the Terumo Interventional Systems division. In Japan, despite strong sales in the Terumo Neuro division, revenue decreased by 0.9% year on year due to lower sales in the Terumo Aortic division. As a result, global revenue increased by 19.2% compared to the same period of the previous fiscal year to ¥188.1 billion.

Medical Care Solutions Company

In Japan, revenue increased by 5.2% year on year, driven by growth in the Hospital Care Solutions and the Pharmaceutical Solutions divisions. Overseas, revenue increased by 30.0% year on year, driven by sales growth primarily in Europe. As a result, global revenue increased by 12.3% compared to the same period of the previous fiscal year to ¥56.6 billion.

Blood and Cell Technologies Company

Overseas, revenue increased by 18.2% year on year as the key businesses in Europe and North America continued to grow. In Japan, revenue increased by 8.5% year on year, supported by solid sales of blood collection-related products. As a result, global revenue increased by 17.7% compared to the same period of the previous fiscal year to ¥60.8 billion.

Terumo Organ Technologies

Following the acquisition of all shares of OrganOx Limited and its consolidation as a wholly owned subsidiary on October 29, 2025, the financial results of OrganOx Limited have been included in the Group's consolidated results from the acquisition date onward.

Revenue in this segment totaled ¥6.2 billion, driven by business expansion primarily in the North American market.

(2) Overview of Consolidated Statement of Financial Position

Total assets increased by ¥61.9 billion to ¥2,374.1 billion. This was mainly attributable to an increase of ¥34.1 billion in cash and cash equivalents due to business expansion, an increase of ¥9.0 billion in other financial assets due to the rise in market prices of listed stocks, and an increase of ¥9.0 billion in trade and other receivables due to the recognition of government grants.

Total liabilities decreased by ¥15.7 billion to ¥712.1 billion. This was mainly attributable to a decrease of ¥13.5 billion in other current liabilities due to bonus payments.

Total equity increased by ¥77.5 billion to ¥1,662.0 billion. This was mainly attributable to an increase of ¥70.4 billion resulting from profit for the period and an increase of ¥29.2 billion in other comprehensive income associated with the yen depreciation, which offset a decrease of ¥22.1 billion due to the payments for dividends from retained earnings.

(3) Cash flow trends

(Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026	Change
Cash flows from operating activities	32,639	74,478	41,838
Cash flows from investing activities	(21,912)	(28,273)	(6,361)
Cash flows from financing activities	(25,830)	(16,191)	9,638
Cash and cash equivalents at the end of the period	204,294	314,633	110,338

Cash flows from operating activities

Net cash provided by operating activities amounted to ¥74.5 billion. The main factors were profit before tax of ¥90.3 billion, depreciation and amortization of ¥27.2 billion, and income taxes paid of ¥24.0 billion.

Cash flows from investing activities

Net cash used in investing activities amounted to ¥28.3 billion. The main factors were ¥12.6 billion for purchase of property, plant and equipment following capital expenditures for manufacturing facilities, ¥6.3 billion for payments for acquisition of shares of subsidiaries, affiliates and other businesses due to additional payments resulting from the finalization of the acquisition consideration of OrganOx Limited, and ¥6.2 billion for purchase of intangible assets following investment in new IT systems.

Cash flows from financing activities

Net cash used in financing activities amounted to ¥16.2 billion. The main factors were repayments of long-term borrowings of ¥160.0 billion, payments for dividends of ¥21.9 billion, redemption of corporate bonds of ¥10.0 billion, proceeds from long-term borrowings of ¥98.8 billion, and proceeds from issue of corporate bonds of ¥79.3 billion.

In addition to the above, there was a ¥4.1 billion increase from the effect of exchange rate changes on cash and cash equivalents. As a result, the balance of cash and cash equivalents as of the end of the period stood at ¥314.6 billion, up ¥34.1 billion from the end of the previous fiscal year.

(4) Future Outlook concerning Consolidated Financial Guidance

We revised upward our full-year consolidated financial guidance for adjusted operating profit, operating profit, and profit for the year attributable to owners of the parent, reflecting the refund of U.S. tariffs and the recognition of settlement proceeds. For details, please refer to the “Notice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2027 (FY2026)” released on August 7, 2026.

2. Condensed Quarterly Consolidated Financial Statements

(1) Condensed Quarterly Consolidated Statement of Financial Position

	(Unit: Millions of yen)	
	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	280,494	314,633
Trade and other receivables	214,927	223,901
Other current financial assets	236	159
Inventories	335,634	341,109
Current tax assets	2,644	1,666
Other current assets	27,102	25,135
Total current assets	861,040	906,605
Non-current assets		
Property, plant and equipment	506,481	508,691
Goodwill and intangible assets	803,410	809,145
Investments accounted for using the equity method	1,544	2,727
Other non-current financial assets	65,085	74,175
Deferred tax assets	45,107	43,387
Other non-current assets	29,565	29,360
Total non-current assets	1,451,194	1,467,488
Total assets	2,312,234	2,374,093

	(Unit: Millions of yen)	
	As of March 31, 2026	As of June 30, 2026
Liabilities and Equity		
Liabilities		
Current liabilities		
Trade and other payables	89,756	79,793
Bonds and borrowings	279,886	179,942
Other current financial liabilities	8,969	9,295
Current tax liabilities	36,830	32,438
Provisions	260	274
Other current liabilities	125,028	111,532
Total current liabilities	540,731	413,275
Non-current liabilities		
Bonds and borrowings	99,910	209,520
Other non-current financial liabilities	39,257	39,298
Deferred tax liabilities	25,671	25,755
Retirement benefit liabilities	6,214	6,155
Provisions	921	928
Other non-current liabilities	15,018	17,136
Total non-current liabilities	186,993	298,794
Total liabilities	727,725	712,070
Equity		
Share capital	38,716	38,716
Capital surplus	51,720	51,782
Treasury shares	(14,517)	(14,468)
Retained earnings	1,116,479	1,164,807
Other components of equity	392,110	421,185
Total equity attributable to owners of the parent	1,584,509	1,662,023
Total equity	1,584,509	1,662,023
Total liabilities and equity	2,312,234	2,374,093

(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income

(Condensed Quarterly Consolidated Statement of Profit or Loss)

	(Unit: Millions of yen)	
	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Revenue	259,965	311,810
Cost of sales	114,498	133,271
Gross profit	145,467	178,538
Selling, general and administrative expenses	91,981	109,699
Other income	4,133	21,198
Other expenses	1,733	556
Operating profit	55,885	89,480
Finance income	873	2,381
Finance costs	1,278	1,476
Share of profit/(loss) of investments accounted for using the equity method	(221)	(63)
Profit before tax	55,259	90,321
Income tax expenses	13,415	19,894
Profit for the period	41,843	70,426
Attributable to:		
Owners of the parent	41,843	70,426
Total profit for the period	41,843	70,426
Earnings per share		
Basic earnings per share (yen)	28.37	47.74
Diluted earnings per share (yen)	28.36	47.73

(Condensed Quarterly Consolidated Statement of Comprehensive Income)

	(Unit: Millions of yen)	
	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Profit for the period	41,843	70,426
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Changes in financial assets measured at fair value through other comprehensive income	(890)	2,095
Total items that will not be reclassified to profit or loss	(890)	2,095
Items that are or may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	(21,298)	27,445
Cost of hedging	-	(388)
Total items that are or may be reclassified subsequently to profit or loss	(21,298)	27,057
Total other comprehensive income for the period	(22,188)	29,152
Total comprehensive income for the period	19,654	99,579
Attributable to:		
Owners of the parent	19,654	99,579
Total comprehensive income for the period	19,654	99,579

(Note) Items in the above statement are net of tax.

(3) Condensed Quarterly Consolidated Statement of Changes in Equity

For the three months ended June 30, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Total equity
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity	Total	
Balance as of April 1, 2025	38,716	51,725	(14,866)	1,016,160	276,800	1,368,535	1,368,535
Profit for the period	-	-	-	41,843	-	41,843	41,843
Other comprehensive income	-	-	-	-	(22,188)	(22,188)	(22,188)
Total comprehensive income	-	-	-	41,843	(22,188)	19,654	19,654
Acquisition of treasury shares	-	-	(0)	-	-	(0)	(0)
Disposal of treasury shares	-	(2)	2	-	(0)	0	0
Dividends	-	-	-	(19,174)	-	(19,174)	(19,174)
Transfer from retained earnings to capital surplus	-	2	-	(2)	-	-	-
Share-based payments	-	57	(0)	-	-	56	56
Total transactions with owners of the parent	-	57	1	(19,176)	(0)	(19,118)	(19,118)
Balance as of June 30, 2025	38,716	51,782	(14,865)	1,038,827	254,610	1,369,071	1,369,071

For the three months ended June 30, 2026

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Total equity
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity	Total	
Balance as of April 1, 2026	38,716	51,720	(14,517)	1,116,479	392,110	1,584,509	1,584,509
Profit for the period	-	-	-	70,426	-	70,426	70,426
Other comprehensive income	-	-	-	-	29,152	29,152	29,152
Total comprehensive income	-	-	-	70,426	29,152	99,579	99,579
Acquisition of treasury shares	-	-	(0)	-	-	(0)	(0)
Disposal of treasury shares	-	(23)	49	-	(26)	0	0
Dividends	-	-	-	(22,126)	-	(22,126)	(22,126)
Transfer from retained earnings to capital surplus	-	23	-	(23)	-	-	-
Transfer from other components of equity to retained earnings	-	-	-	50	(50)	-	-
Share-based payments	-	61	(0)	-	-	61	61
Total transactions with owners of the parent	-	61	48	(22,098)	(76)	(22,064)	(22,064)
Balance as of June 30, 2026	38,716	51,782	(14,468)	1,164,807	421,185	1,662,023	1,662,023

(4) Condensed Quarterly Consolidated Statement of Cash Flows

	(Unit: Millions of yen)	
	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Cash flows from operating activities		
Profit before tax	55,259	90,321
Depreciation and amortization	21,183	27,190
Impairment losses	13	-
Share of (profit)/loss of investments accounted for using the equity method	221	63
Increase/(decrease) in retirement benefit assets or liabilities	509	180
Interest and dividend income	(851)	(1,656)
Interest expenses	475	1,476
Foreign exchange (gain)/loss	(2,118)	(1,873)
(Gain)/loss on sale and disposal of property, plant and equipment	65	12
(Increase)/decrease in trade and other receivables	(5,942)	(6,589)
(Increase)/decrease in inventories	(10,501)	(3,176)
Increase/(decrease) in trade and other payables	(2,453)	(3,726)
Others	(8,113)	(4,322)
Sub-total	47,749	97,900
Interest and dividend income received	834	1,841
Interest expenses paid	(723)	(1,226)
Income taxes paid	(15,220)	(24,037)
Net cash provided by operating activities	32,639	74,478
Cash flows from investing activities		
Payments into time deposits	(126)	(558)
Proceeds from withdrawal of time deposits	200	335
Payments for purchase of property, plant and equipment	(16,994)	(12,608)
Proceeds from sale of property, plant and equipment	46	48
Payments for purchase of intangible assets	(3,287)	(6,211)
Proceeds from government grants	67	224
Payments for purchase of financial instruments	(1,750)	(3,317)
Proceeds from sale of financial instruments	-	100
Payments for acquisition of shares of subsidiaries, affiliates and other businesses	(67)	(6,285)
Net cash used in investing activities	(21,912)	(28,273)

(Unit: Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Cash flows from financing activities		
Increase/(decrease) in short-term borrowings and commercial paper	10,000	-
Proceeds from long-term borrowings	-	98,770
Repayments of long-term borrowings	(15,000)	(160,000)
Proceeds from issue of corporate bonds	-	79,262
Redemption of corporate bonds	-	(10,000)
Repayments of lease liabilities	(1,845)	(2,326)
Payments for purchase of treasury shares	(0)	(0)
Payments for dividends	(18,984)	(21,898)
Net cash used in financing activities	(25,830)	(16,191)
Effect of exchange rate changes on cash and cash equivalents	(2,475)	4,126
Net increase/(decrease) in cash and cash equivalents	(17,578)	34,139
Cash and cash equivalents at the beginning of the period	221,872	280,494
Cash and cash equivalents at the end of the period	204,294	314,633

(5) Notes to Condensed Quarterly Consolidated Financial Statements

(i) Going concern assumption

Not applicable

(ii) Change in accounting policy

The Group has adopted the standard and interpretation below from the first quarter of the fiscal year ending March 31, 2027.

Standard/Interpretation		Outline of the new standards, interpretations and amendments
		Amendments to the classification, measurement and disclosure of financial instruments (IFRS 9 and IFRS 7)
IFRS 9	Financial Instruments	• Clarifying the classification of financial assets with environmental, social and governance (ESG) and similar features
IFRS 7	Financial Instruments: Disclosures	• Derecognition of a financial liability settled through electronic transfer
		• Disclosure regarding investments in equity instruments designated at fair value through other comprehensive income

There is no material effect of adopting the amendment on the Group's condensed quarterly consolidated financial statements.

(iii) Segment information

(1) General information on reportable segments

The Group's reportable segments are components of the Group for which discrete financial information is available and which are regularly reviewed by the Board of Directors for the purposes of allocating management resources and evaluating business performance.

The Group has adopted an internal company structure organized by product groups. Each internal company headquarters formulates comprehensive strategies for its respective products in both Japan and overseas and conducts its business activities accordingly.

Following the acquisition of all shares of OrganOx Limited on October 29, 2025, making it a wholly owned subsidiary, "Terumo Organ Technologies" was added as a reportable segment in the previous fiscal year.

Accordingly, the Group has designated four reportable segments based on its internal company structure and product group classifications: the Cardiac and Vascular Company, the Medical Care Solutions Company, the Blood and Cell Technologies Company, and Terumo Organ Technologies.

(2) Reportable segment information

Revenue and performance by the reporting segments of the Group are as follows.

For the three months ended June 30, 2025

	Reportable Segments					(Unit: Millions of yen)	Amount recorded on condensed quarterly consolidated financial statements
	Cardiac and Vascular Company	Medical Care Solutions Company	Blood and Cell Technologies Company	Terumo Organ Technologies	Total	Adjustments (Note 1)	
Revenue							
Revenue from sales to external customers	157,827	50,402	51,646	-	259,876	89	259,965
Segment profit (Adjusted operating profit)	45,678	6,664	7,036	-	59,378	(274)	59,103
(Adjustment items)							
Amortization of intangible assets acquired through business combinations	(2,366)	-	(2,782)	-	(5,148)	74	(5,073)
Non-recurring profit or loss (Note 2)							1,855
Operating profit							55,885
Finance income							873
Finance costs							(1,278)
Share of profit/(loss) of investment accounted for using the equity method							(221)
Profit before tax							55,259

(Note 1) Amounts in Adjustments are as follows:

- ¥89 million adjustment to Revenue from sales to external customers is mainly proceeds from outward temporary staffing that is not attributable to reportable segments.
- ¥(274) million adjustment to Segment profit consists of ¥(450) million for preparation expenses to comply with Medical Device Regulation in the EU and ¥205 million for inventories.

(Note 2) ¥1,855 million Non-recurring profit or loss mainly includes ¥3,152 million for loss compensation due to the termination of the new contract manufacturing project with a pharmaceutical company and ¥(1,277) million for business reorganization expenses.

For the three months ended June 30, 2026

	Reportable Segments					(Unit: Millions of yen)	Amount recorded on condensed quarterly consolidated financial statements
	Cardiac and Vascular Company	Medical Care Solutions Company	Blood and Cell Technologies Company	Terumo Organ Technologies	Total	Adjustments (Note 1)	
Revenue							
Revenue from sales to external customers	188,141	56,587	60,776	6,225	311,730	79	311,810
Segment profit (Adjusted operating profit)	59,971	7,076	11,135	940	79,123	484	79,607
(Adjustment items)							
Amortization of intangible assets acquired through business combinations	(2,592)	(8)	(2,936)	(1,593)	(7,130)	(81)	(7,211)
Non-recurring profit or loss (Note 2)							17,084
Operating profit							89,480
Finance income							2,381
Finance costs							(1,476)
Share of profit/(loss) of investment accounted for using the equity method							(63)
Profit before tax							90,321

(Note 1) Amounts in Adjustments are as follows:

- (1) ¥79 million adjustment to Revenue from sales to external customers is mainly proceeds from outward temporary staffing that is not attributable to reportable segments.
- (2) ¥484 million adjustment to Segment profit consists of ¥(333) million for preparation expenses to comply with Medical Device Regulation in the EU and ¥586 million for inventory adjustments.

(Note 2) ¥17,084 million Non-recurring profit or loss includes ¥20,110 million for recognition of settlement proceeds and ¥(2,561) million for expense related to the inventory step-up arising from fair value measurement of acquired assets in the acquisition of OrganOx Limited.

(iv) Material subsequent events

Issuance of bonds

In accordance with the resolution of the Board of Directors held on March 19, 2026, the Company issued unsecured straight bonds with a payment date of July 24, 2026, under the following terms and conditions.

Terumo Corporation 12th series Unsecured Straight Bonds with inter-bond pari passu clause (2-year bond)

1. Issue size: ¥40 billion
2. Issue price: 100 yen per 100 yen of each bond amount
3. Coupon rate: 1.716% per annum
4. Payment due date: July 24, 2026
5. Maturity date: July 24, 2028
6. Redemption method: full redemption upon maturity
7. Use of proceeds: to be allocated to a repayment of borrowings due at the end of October 2026